Free Flow, Inc. (FFLO) Announces First Agreement to Acquire Pharmaceutical Business, Appoints New Chairman of the Board Page 1

The proposed acquisition is expected to have an enterprise value of approximately $10 million and expected gross revenue in 2024 of up to $7 million.

NORTH BERGEN, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) — Free Flow, Inc. (FFLO:OTCPK), incorporated in the State of Delaware as Free Flow USA, Inc., today announced that the company has signed a letter of intent (LOI) to acquire an over-the-counter pharmaceutical wholesaler/contract manufacturer with gross revenues of $4.4 million in 2023 and expected revenues of approximately $7 million in 2024. Under the terms of the agreement, the acquired business will be a wholly owned subsidiary of FFLO and, along with additional potential acquisitions in the pharmaceutical industry, is expected to become the primary focus of the company’s operations. Concurrently, FFLO is exploring the potential acquisition of another entity in the same industry with annual revenues greater than $70 million.